Nara
← Intervention Library

Experimental and investigational

Senolytics

Clearing senescent cells — a strong mechanism with thin canine data.

Nara’s current positionResearch watchlist
Evidence briefing

Strongest directness: Canine healthspan / clinical outcomes. Last reviewed 2026-08-12.

Nara’s evidence view

Research watchlist

PreliminaryCanine healthspan or clinical outcomesLow confidence

The claim we’re evaluating

Senolytic interventions are biologically plausible geroscience interventions in dogs, but current canine evidence does not establish that selective removal of senescent cells improves objective function, healthspan, or lifespan.

Nara’s interpretation

Senescent-cell biology is a credible geroscience target, but that is not the same as showing that a particular senolytic improves meaningful outcomes in dogs. A randomized canine trial of a senolytic plus NAD+ precursor combination produced an owner-reported cognitive signal, but objective cognitive testing and measured activity did not significantly improve. Nara should therefore treat senolytics as investigational rather than implying that canine anti-aging benefit has been established.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

A 2024 randomized controlled trial enrolled 70 older dogs with mild-to-moderate cognitive impairment to placebo, low-dose, or full-dose LY-D6/2, a combination containing a senolytic intervention and an NAD+ precursor. Fifty-nine dogs reached the 3-month primary endpoint. Change in owner-reported CCDR differed significantly between groups, with the largest improvement in the full-dose group, but there was no significant between-group difference on in-house cognitive testing or objectively measured physical activity. Frailty, owner-reported activity, and happiness showed nonsignificant favorable patterns, adverse events were distributed similarly between groups, and all groups improved on several measures. The study does not isolate the senolytic component from the NAD+ component, demonstrate senescent-cell target engagement, or test lifespan.

What is not known

The principal canine randomized trial tested a multi-component senolytic plus NAD+ precursor intervention, so any observed effect cannot be attributed specifically to senolysis. The statistically significant finding was based on an owner-reported cognitive scale; objective in-house cognition and activity-monitor outcomes were not significantly different between groups. No validated senescent-cell target engagement connected the clinical signal to the proposed mechanism. There is no canine lifespan trial demonstrating that a senolytic extends life, and no replicated demonstration of broad canine healthspan improvement.

Current position

Senescent-cell biology is a credible geroscience target, but that is not the same as showing that a particular senolytic improves meaningful outcomes in dogs. A randomized canine trial of a senolytic plus NAD+ precursor combination produced an owner-reported cognitive signal, but objective cognitive testing and measured activity did not significantly improve. Nara should therefore treat senolytics as investigational rather than implying that canine anti-aging benefit has been established.

A 2024 randomized controlled trial enrolled 70 older dogs with mild-to-moderate cognitive impairment to placebo, low-dose, or full-dose LY-D6/2, a combination containing a senolytic intervention and an NAD+ precursor. Fifty-nine dogs reached the 3-month primary endpoint. Change in owner-reported CCDR differed significantly between groups, with the largest improvement in the full-dose group, but there was no significant between-group difference on in-house cognitive testing or objectively measured physical activity. Frailty, owner-reported activity, and happiness showed nonsignificant favorable patterns, adverse events were distributed similarly between groups, and all groups improved on several measures. The study does not isolate the senolytic component from the NAD+ component, demonstrate senescent-cell target engagement, or test lifespan.